抗凝血酶对凝血酶、因子Xa、因子IXa、因子XIa、因子XIIa和激肽释放酶抑制作用中，肝素促速率效应的分子量依赖性。
The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin.
作者信息
Holmer E, Kurachi K, Söderström G
出版信息
Biochem J. 1981 Feb 1;193(2):395-400. doi: 10.1042/bj1930395.
Abstract
Heparin fractions of different molecular weight and with high affinity for antithrombin were studied with respect to their ability to potentiate the inhibition of activated clotting factors by antithrombin. Inhibition of thrombin, Factor IXa and Factor XIa showed similarities in the dependence on the molecular weight of heparin and was found to decrease with decreasing molecular weight. Inactivation of Factor Xa, Factor XIIa and kallikrein was, however, less dependent on the size of the polysaccharide and, to a great extent, was potentiated even by low-molecular-weight heparin fractions that had virtually no effect on the inhibition of thrombin, Factor IXa and Factor XIa.
摘要
研究了不同分子量且对抗凝血酶具有高亲和力的肝素组分增强抗凝血酶对活化凝血因子抑制作用的能力。凝血酶、因子IXa和因子XIa的抑制在对肝素分子量的依赖性方面表现出相似性，并且发现随着分子量的降低而降低。然而，因子Xa、因子XIIa和激肽释放酶的失活对多糖大小的依赖性较小，并且在很大程度上，即使是对凝血酶、因子IXa和因子XIa的抑制几乎没有作用的低分子量肝素组分也能增强其失活作用。
相似文献
1
The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin.抗凝血酶对凝血酶、因子Xa、因子IXa、因子XIa、因子XIIa和激肽释放酶抑制作用中，肝素促速率效应的分子量依赖性。
Biochem J. 1981 Feb 1;193(2):395-400. doi: 10.1042/bj1930395.
2
Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates.利用氨基酸和肽硫酯对牛凝血酶、因子IXa、因子Xa、因子XIa、因子XIIa、血浆激肽释放酶和胰蛋白酶的活性位点进行定位：新型敏感底物的开发
Biochemistry. 1981 Dec 8;20(25):7196-206. doi: 10.1021/bi00528a022.
3
Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.合成寡糖对凝血和纤维蛋白溶解系统蛋白酶抗凝血酶抑制作用的加速能力。与肝素和低分子肝素的比较。
Thromb Haemost. 2004 Nov;92(5):929-39. doi: 10.1160/TH04-06-0384.
4
Effect of heparin on the inhibition of the contact system enzymes.肝素对接触系统酶抑制作用的影响。
Ann N Y Acad Sci. 1989;556:95-103. doi: 10.1111/j.1749-6632.1989.tb22493.x.
5
Formation of the fibrin clot: the balance of procoagulant and inhibitory factors.纤维蛋白凝块的形成：促凝血因子与抑制因子的平衡。
Clin Haematol. 1985 Jun;14(2):281-342.
6
[Pharmacology of heparin].[肝素的药理学]
Z Gesamte Inn Med. 1979 Jan 1;34(1):3-8.
7
Effect of heparin on the inactivation rate of human factor XIa by antithrombin-III.肝素对抗凝血酶III灭活人因子XIa速率的影响。
Blood. 1982 Oct;60(4):940-7.
8
Evidence for a plasma inhibitor of the heparin accelerated inhibition of factor Xa by antithrombin III.抗凝血酶III对因子Xa肝素加速抑制作用存在血浆抑制剂的证据。
Biochim Biophys Acta. 1979 Sep 3;586(3):584-93. doi: 10.1016/0304-4165(79)90049-7.
9
Inhibition of factor IXa and factor Xa by antithrombin III/heparin during factor X activation.在因子X激活过程中抗凝血酶III/肝素对因子IXa和因子Xa的抑制作用。
J Biol Chem. 1988 Oct 25;263(30):15313-8.
10
Effects of heparin fractions of different affinities to antithrombin III and thrombin on the inactivation of thrombin and factor Xa by antithrombin III.不同抗凝血酶III亲和力和凝血酶亲和力的肝素组分对抗凝血酶III使凝血酶和因子Xa失活的影响。
Can J Biochem Cell Biol. 1984 Oct;62(10):975-83. doi: 10.1139/o84-125.
引用本文的文献
1
Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?用于心房颤动导管消融的不间断直接口服抗凝剂方案：直接口服抗凝剂水平重要吗？
Front Cardiovasc Med. 2022 Mar 29;9:864899. doi: 10.3389/fcvm.2022.864899. eCollection 2022.
2
Heparin affects the induction of regulatory T cells independent of anti-coagulant activity and suppresses allogeneic immune responses.肝素通过非抗凝血活酶活性影响调节性 T 细胞的诱导，并抑制同种异体免疫反应。
Clin Exp Immunol. 2020 Oct;202(1):119-135. doi: 10.1111/cei.13480. Epub 2020 Jul 15.
3
Revisiting the Pharmacology of Unfractionated Heparin.重新审视未分级肝素的药理学。
Clin Pharmacokinet. 2019 Aug;58(8):1015-1028. doi: 10.1007/s40262-019-00751-7.
4
Structural Characterization and Repair Mechanism of Sulfated Polysaccharides of Different Molecular Weights on Damaged Renal Epithelial Cells.不同分子量硫酸多糖对受损肾上皮细胞的结构特征及修复机制研究。
Oxid Med Cell Longev. 2018 Aug 5;2018:7410389. doi: 10.1155/2018/7410389. eCollection 2018.
5
Visualizing correlated motion with HDBSCAN clustering.使用HDBSCAN聚类可视化相关运动。
Protein Sci. 2018 Jan;27(1):62-75. doi: 10.1002/pro.3268. Epub 2017 Sep 6.
6
Heparan sulfate/heparin glycosaminoglycan binding alters inhibitory profile and enhances anticoagulant function of conserved Amblyomma americanum tick saliva serpin 19.硫酸乙酰肝素/肝素糖胺聚糖结合改变了美洲钝眼蜱唾液丝氨酸蛋白酶抑制剂19的抑制谱并增强了其抗凝功能。
Insect Biochem Mol Biol. 2017 Jan;80:1-10. doi: 10.1016/j.ibmb.2016.11.002. Epub 2016 Nov 12.
7
Uncovering Large-Scale Conformational Change in Molecular Dynamics without Prior Knowledge.在无需先验知识的情况下揭示分子动力学中的大规模构象变化。
J Chem Theory Comput. 2016 Dec 13;12(12):6130-6146. doi: 10.1021/acs.jctc.6b00757. Epub 2016 Nov 10.
8
A purification process for heparin and precursor polysaccharides using the pH responsive behavior of chitosan.一种利用壳聚糖的pH响应特性对肝素和前体多糖进行纯化的方法。
Biotechnol Prog. 2015 Sep-Oct;31(5):1348-59. doi: 10.1002/btpr.2144. Epub 2015 Jul 16.
9
Combinatorial one-pot chemoenzymatic synthesis of heparin.肝素的组合一锅法化学酶促合成
Carbohydr Polym. 2015 May 20;122:399-407. doi: 10.1016/j.carbpol.2014.10.054. Epub 2014 Nov 7.
10
Update on the safety and bioequivalence of biosimilars - focus on enoxaparin.生物类似药的安全性和生物等效性最新进展——聚焦依诺肝素
Drug Healthc Patient Saf. 2013 Jun 10;5:133-41. doi: 10.2147/DHPS.S28813. Print 2013.
本文引用的文献
1
A modified uronic acid carbazole reaction.一种改良的糖醛酸咔唑反应。
Anal Biochem. 1962 Oct;4:330-4. doi: 10.1016/0003-2697(62)90095-7.
2
Inhibition of the thrombin-fibrinogen reaction by heparin and purified cofactor.肝素和纯化辅因子对凝血酶-纤维蛋白原反应的抑制作用。
Scand J Haematol. 1968;5(6):440-53. doi: 10.1111/j.1600-0609.1968.tb00865.x.
3
Biological properties of the naturally occurring plasma inhibitor to activated factor X.天然存在的血浆活化因子X抑制剂的生物学特性。
J Biol Chem. 1971 Jun 10;246(11):3703-11.
4
Isolation and characterization of bovine factor IX (Christmas factor).牛凝血因子IX（克里斯马斯因子）的分离与特性鉴定。
Biochemistry. 1973 Nov 20;12(24):4938-45. doi: 10.1021/bi00748a019.
5
Bovine factor X 1 (Stuart factor). Mechanism of activation by protein from Russell's viper venom.牛凝血因子X1（斯图尔特因子）。被锯鳞蝰蛇毒中的蛋白质激活的机制。
Biochemistry. 1972 Dec 19;11(26):4892-9. doi: 10.1021/bi00776a003.
6
Anticoagulant action of heparin.肝素的抗凝作用。
Nature. 1973 Dec 7;246(5432):355-7. doi: 10.1038/246355a0.
7
The mechanism of activation of bovine factor IX (Christmas factor) by bovine factor XIa (activated plasma thromboplastin antecedent).牛因子XIa（活化血浆促凝血酶原激酶前体）激活牛因子IX（克里斯马斯因子）的机制。
Biochemistry. 1974 Oct 22;13(22):4508-16. doi: 10.1021/bi00719a006.
8
Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin.肝素的抗凝活性：通过固定化抗凝血酶亲和色谱法分离高活性和低活性肝素种类
FEBS Lett. 1976 Jul 1;66(1):90-3. doi: 10.1016/0014-5793(76)80592-3.
9
The separation of active and inactive forms of heparin.肝素活性形式与非活性形式的分离。
Biochem Biophys Res Commun. 1976 Mar 22;69(2):570-7. doi: 10.1016/0006-291x(76)90558-1.
10
Inhibition of bovine factor IXa and factor Xabeta by antithrombin III.抗凝血酶III对牛因子IXa和因子Xabeta的抑制作用。
Biochemistry. 1976 Jan 27;15(2):373-7. doi: 10.1021/bi00647a021.
Zotero 插件